Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809489 | 0.91 | KDR (0.80) | KDR | |
| SCHEMBL4813427 | 0.89 | KDR (1.00) | KDR | |
| SCHEMBL4804557 | 0.88 | KDR (0.85) | KDR | |
| SCHEMBL4816066 | 0.87 | KDR (0.83) | KDR | |
| SCHEMBL4814968 | 0.87 | KDR (0.77) | KDR | |
| SCHEMBL4814457 | 0.86 | KDR (1.00) | KDR | |
| SCHEMBL13980535 | 0.86 | KDR (0.76) | KDR | |
| SCHEMBL4806044 | 0.86 | KDR (1.00) | KDR | |
| SCHEMBL13980541 | 0.85 | KDR (0.78) | KDR | |
| SCHEMBL6676871 | 0.85 | KDR (0.75) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-04-21 | — | — | US | claimed |
| US-7459455-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | TIE1, TEK, KDR | KDR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.